About Anabios
Anabios is a Healthcare company based in San Diego (United States) founded in 2009. Ex-vivo human tissue studies are performed for preclinical drug discovery. Anabios has raised $24.78 million across 12 funding rounds from investors including NIH, HHS and Ampersand Capital Partners. The company has 51 employees. Anabios has completed 1 acquisition, including Cell Systems. Anabios offers products and services including Human Tissue and Cells, Functional Assays, Human Hepatocytes, and Human Precision-Cut Lung Slices. Its focus areas include Biopharma Outsourcing, CRO, Drug Discovery and In Vitro Assays. Its legal entity is ANABIOS CORPORATION. Its competitors include Quiver Bioscience, Zen-Bio and Rules-Based Medicine; 1 of its 3 listed competitors has raised funding.
Company details
AnaBios provides contract research services for pre-clinical drug discovery which is entirely based on laboratory tests performed in living human tissues. It provides services for target selection and validation, lead optimisation, clinical candidate selection and clinical program de-risking through its proprietary Phase X platform. It offers its clients and partners full access to its assays and technologies that enable the study of ex-vivo human responses to drugs and the investigation of the molecular and functional basis of human physiology. The company focuses primarily on ex-vivo human studies for cardiovascular safety, pain and neurodegeneration. The company claims that its human-focused approach is a better predictor of safety and efficacy of drugs than the traditional in vitro or animal studies. The company also claims to have validated its technologies through its collaborations with pharma companies in US, Europe and Japan and has now initiated its own portfolio of drugs targeting CNS and Cardiovascular diseases. AnaBios has licensed a suite of patents for Nav1.7 sodium ion channel blockers from Purdue Pharma from which it will help in finding suitable candidates through its Phase X platform. The company also offers cardiac safety and toxicity and neurotoxicity services.
- Headquarters San Diego, United States
- Employees 51
- SectorsHealthcare
- Email••••••••
- Website anabios.com
- Social LinkedIn X Facebook
- Legal Name Anabios Corporation
- Total Equity Funding$24.78M (USD)
in 12 rounds
- Latest Funding Round$6.5M (USD), Series B
Jun 2022
- InvestorsNIH
& 6 more
- Employee Count51
- Investments & Acquisitions
Products & Services of Anabios
Anabios offers a comprehensive portfolio of products and services, including Human Tissue and Cells, Functional Assays, Human Hepatocytes, and Human Precision-Cut Lung Slices.
Provides human tissues for scientific research and drug testing.
Offers assays for evaluating drug effects on human tissues.
Specific human liver cells for research applications.
Human lung tissue slices for toxicity and efficacy studies.
Funding Insights of Anabios
Anabios has successfully raised a total of $24.78M across 12 strategic funding rounds. The most recent funding activity was a Series B round of $6.5 million completed in June 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $24.78M
- Total Rounds 12
- Last Round Series B — $6.5M
- First Round $1.32M
(Sep 2011)
- Investors Count 7
Latest 10 of 12 funding rounds of Anabios with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2022 | $6.5M | Series B | – | – | |
| Sep 2021 | $1.73M | Grant | – | – | |
| Sep 2021 | $1.42M | Grant | – | – | |
| Sep 2020 | $320,054 | Grant | – | – | |
| Jun 2020 | $1.14M | Series B | – | – | – |
| Mar 2020 | $1.13M | Grant | – | – | |
| Sep 2019 | Grant | – | – | ||
| Jun 2017 | $5.75M | Series B | – | – | – |
| Dec 2016 | $10M | Series B | – | Principia SGR | – |
| Jun 2014 | $200,651 | Grant | – | – |
7 investors in total: 7 institutional.
Investors in Anabios
Anabios has secured backing from 7 investors, including venture fund and institutional investors. Prominent investors backing the company include NIH, HHS and Ampersand Capital Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Ampersand Capital Partners is focused on investments in healthcare and life sciences. | ampersandcapital.com | Boston, United States | ||
Early-stage investments in Italian tech and life sciences are targeted. | principiasgr.it | Milano, Italy | ||
Angel Network for companies based in Southern California | techcoastangels.com | Los Angeles, United States | ||
Drug discovery services are provided to the biopharma sector. | 1887 | nih.gov | United States | |
Public health and human services are overseen by HHS. | 1953 | hhs.gov | ||
The U.S. Food and Drug Administration is tasked with regulating food, drugs, and medical products. | fda.gov | United States | ||
Business education and research are provided by Rady School. | rady.ucsd.edu | La Jolla, United States |
Investor details for Anabios
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Anabios
9 people are tracked at Anabios (4 in leadership, 5 in board & advisors); the tracked headcount is 51.
| Name | Role | Group |
|---|---|---|
Caroline Choe, CPA | Head of Accounting | Leadership |
Andre Ghetti | CEO | Leadership |
Gary W. | Director of Marketing | Leadership |
Dr Najah Abi-Gerges | Senior Vice President, Research Alliances | Leadership |
Peter Crowley | Executive Chairman | Board & advisors |
David Anderson | Board Member | Board & advisors |
Ric Erdman | Board Member | Board & advisors |
Jack A. Reynolds | Co-Founder & Chairman Emeritus | Board & advisors |
Melanie Fan | Board Member | Board & advisors |
Complete people profiles for Anabios
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Anabios
Anabios has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Cell Systems.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Primary cells, culture media, and reagents are developed and manufactured. | cell-systems.com | Kirkland, United States | 1989 | Apr 2023 | •••• |
Complete acquisition details for Anabios
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Anabios
4 dated milestones of Anabios across 14 years, from founding to its latest funding, stage changes and deals.
- Founded Anabios is founded.
- Funding First funding round of $1.3M.
- Funding Latest funding round, Series B, of $6.5M.
- Acquisition Acquires Cell Systems.
Competitors of Anabios
Anabios has 3 listed competitors in our database, 1 of them funded. They include Quiver Bioscience, Zen-Bio and Rules-Based Medicine.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| quiverbioscience.com | 2013 | Cambridge, United States | Developer of transformational medicines for neurological disorders | |||
| zen-bio.com | 1995 | Durham, United States | Cell-based solutions are provided to accelerate therapy discovery and development. | |||
| rulesbasedmedicine.com | 2002 | Austin, United States | $25M | Multiplexed immunoassays for protein biomarkers are developed via proprietary platform. |
Detailed competitors of Anabios
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Anabios
The website of Anabios (anabios.com) receives about 3.6K visits a month.
- Monthly visits3.6K
▲ 6.8% vs previous month
Websites whose visitors overlap most with Anabios. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| curemetrix.com | 100% | 2.7K | #5,895,624 | View details | |
| mabplexinc.com | 97% | 1K | #15,283,808 | View details | |
vastekgroup.com | vastekgroup.com | 95% | #4,627,539 | – | |
electromeds.com | electromeds.com | 94% | – | ||
| excellos.com | 94% | 3.5K | #4,545,602 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 19 similar websites and full traffic analytics for Anabios
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 19 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Biopharma Outsourcing & Drug Delivery
3 companies that operate in the same segment as Anabios (Biopharma Outsourcing & Drug Delivery) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Suite solutions are provided for payers and healthcare providers. | 1998 | Princeton, New Jersey, United States | USD 220 M | USD 374.1 M | 4,490 | |
Wearable insulin infusion systems are developed for diabetes patients. | 2000 | Boston, Massachusetts, United States | USD 120.4 M | USD 2.71 B | 3,900 | |
Developer of small-molecule drugs | 1991 | Los Angeles, California, United States | USD 50 M | USD 348.97 M | 407 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Anabios
Complete news archive for Anabios
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Anabios
Anabios was founded in 2009 and raised its 1st funding round 2 years after it was founded.
Anabios is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Anabios is a funded company, having raised a total of $24.78M across 12 funding rounds to date. The company's 1st funding round was a Grant of $200.65K, raised on Sep 2011.
Anabios has 51 employees.
AnaBios provides contract research services for pre-clinical drug discovery which is entirely based on laboratory tests performed in living human tissues. It provides services for target selection and validation, lead optimisation, clinical candidate selection and clinical program de-risking through its proprietary Phase X platform. It offers its clients and partners full access to its assays and technologies that enable the study of ex-vivo human responses to drugs and the investigation of the molecular and functional basis of human physiology. The company focuses primarily on ex-vivo human studies for cardiovascular safety, pain and neurodegeneration. The company claims that its human-focused approach is a better predictor of safety and efficacy of drugs than the traditional in vitro or animal studies. The company also claims to have validated its technologies through its collaborations with pharma companies in US, Europe and Japan and has now initiated its own portfolio of drugs targeting CNS and Cardiovascular diseases. AnaBios has licensed a suite of patents for Nav1.7 sodium ion channel blockers from Purdue Pharma from which it will help in finding suitable candidates through its Phase X platform. The company also offers cardiac safety and toxicity and neurotoxicity services.
Anabios's top competitors include Quiver Bioscience, Zen-Bio and Rules-Based Medicine.
Anabios offers Human Tissue and Cells, Functional Assays, Human Hepatocytes, and Human Precision-Cut Lung Slices.
Anabios has made 1 acquisition, including Cell Systems.
Anabios has 7 investors. Key investors include NIH, HHS, Ampersand Capital Partners, U.S. Food and Drug Administration, and Principia SGR.
Anabios operates through Anabios Corporation.